Oxxiom measures arterial oxygen saturation (SpO2), pulse rate, and pulse strength at the measurement site (perfusion index).
Oxxiom is expected to ship in Q2 2016. Oxxiom is not yet cleared by the FDA for clinical use as a medical device.
Oxxiom’s innovative design has combined the electronics and biosensing technology of a clinical grade pulse oximeter into a tiny, easy-to-use, and completely wireless device that offers over 24 hours of continuous monitoring. Oxxiom weighs only 0.12 ounces (3.5 grams) and is completely disposable, eliminating the need for sterilization and significantly reducing the risks of cross contamination.
Oxxiom’s proprietary technology offers total mobility in a 30 feet range and allows users to sleep in any position, exercise, use the restroom, wash their hands, or take a shower while connected to the device. Oxxiom is monitor agnostic, and works with mobile devices, tablets, laptops and desktops. Oxxiom does not require external batteries or battery chargers.
Pulse oximetry is a technology that enables the non-invasive monitoring of a patient’s arterial oxygen saturation, pulse rate, and perfusion index and gives doctors an indication of the patient’s cardiorespiratory status. Pulse oximeters are widely utilized on procedures that require anesthesia or sedation, and during sleep monitoring studies. They are also used to monitor conditions that affect oxygen blood levels—such as heart attack, heart failure, anemia, COPD, and apnea. True Wearables is a medical device startup founded in 2014 by Marcelo Lamego (Ph.D. Stanford University), previously of The Boston Consulting Group, Masimo, Cercacor and Apple.
Size: 1.2 x 0.7 x 0.3 inches (30 x 17 x 7.5 mm).
Weight: 0.12 ounces (3.5 grams).
Wireless Range: 33 feet (10 meters).
Battery Life: over 24 hours.
SpO2 Accuracy (70-100%): +/-3% on 68% of the population.
Pulse Rate Accuracy (25-250BPM): +/-3BPM on 68% of the population.
Specifications are subject to change without notice.
If you wish to learn more about Oxxiom or if you are a healthcare provider and would like to evaluate Oxxiom in an independent clinical study, please contact us at: